FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
DiagnaMed Holdings (CSE: DMED) has officially launched its Brain Age Brain Health AI solution in Canada. Clinics across the country are now able to apply to add the solution to their offerings for supporting brain health.
Brain Age Brain Health AI is a novel solution that estimates brain age and provides a health score for the brain. The tech, based on research and development conducted at the University of Miami and Drexel University, estimates brain age by collecting neural activity data using an electroencephalogram headset, and then calculates the result using a proprietary machine-learning model.
READ: DiagnaMed Secures Trademark For BRAIN AGE Brand In Canada
The tool ultimately provides a score for the brain using a clinically validated assessment for brain performance, resilience, and vulnerability functions. That score can then be used to determine if a person has a healthy brain or if they are in early stages of cognitive decline.
The solution has been made available to Canadian-based clinics that focus on health and wellness, sports and physical therapy, chiropractic care, mental health, or clinical and academic research that is focused on cognitive and neurological disorders. The tool has been made available at BrainAge.ca.
DiagnaMed Holdings last traded at $0.035 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
